记者丨 高江虹 实习生陈晓冉 编辑丨张伟贤 这大概是美妆巨头雅诗兰黛二十年来最大的亏损。 8月20日晚间，雅诗兰黛发布截至6月30日的2025财年Q4及全年业绩报告。尽管已积极调整战 略方向，但雅诗兰黛业绩依旧低迷。2025财年，其净销售额为143.26亿美元，同比下滑8%， 净利润同比暴跌390%，从上一年的盈利3.9亿美元变为亏损11.33亿美元。 这份业绩一出炉，股价立即跳水。当日，雅诗兰黛美股盘前一度跌近15%。截至美东时间周五 收盘，股价为91.23美元，而2022年年初时其股价曾高达374.2美元。 华尔街金融巨头摩根士丹利发布研报，维持对雅诗兰黛股票的"中性"看跌评级， 并预计雅诗 兰黛股价将进一步下跌， 未来12个月内潜在跌幅超过20%。 对此，雅诗兰黛管理层对此泰然自若，"业绩整体符合预期，"雅诗兰黛集团总裁兼首席执行官 司泰峰（Stéphane de La Faverie）表示，有信心在2026财年实现有机销售额增长，开始重建 营运盈利能力，并在未来几年实现稳健的两位数调整后营业利润率。 值得关注的是，自2026财年Q1起，雅诗兰黛集团调整区域架构，未来中国大陆将作为独立地 区进行业绩列报 ...

21世纪经济报道记者高江虹、实习生陈晓冉 护肤品作为曾经的顶梁柱，这次摔得最狠。财报直指 Estée Lauder 和 La Mer 两大核心品牌拖了后腿。 具体来看，亚洲旅游零售业务疲软，中国消费者出国消费的热情降温，免税店订单跟着缩水；Dr.Jart + 在中韩市场第四季度业绩也远不如预期。唯有The Ordinary 靠着精准触达消费者，还能保持中个位数增 长。 这大概是美妆巨头雅诗兰黛二十年来最大的亏损。 8月20日晚间，雅诗兰黛发布截至6月30日的2025财年Q4及全年业绩报告。尽管已积极调整战略方向， 但雅诗兰黛业绩依旧低迷。2025财年，其净销售额为143.26亿美元，同比下滑8%，净利润同比暴跌 390%，从上一年的盈利3.9亿美元变为亏损11.33亿美元。 这份业绩一出炉，股价立即跳水。当日，雅诗兰黛美股盘前一度跌近15%。目前雅诗兰黛的股价仅为 87.72美元，而2022年年初时其股价曾高达374.2美元。 华尔街金融巨头摩根士丹利发布研报，维持对雅诗兰黛股票的"中性"看跌评级，并预计雅诗兰黛股价将 进一步下跌，未来12个月内潜在跌幅超过20%。 对此，雅诗兰黛管理层对此泰然自若，"业绩整 ...

Core Viewpoint - Estee Lauder Companies Inc. is set for a significant turnaround driven by its "Beauty Reimagined" strategy, despite recent challenges, particularly in Asia, with a forecasted stock price increase of 30% [1][2]. Group 1: Financial Performance and Projections - The company is expected to achieve a 4% revenue CAGR through fiscal year 2027 and a margin expansion of 430 basis points to 12%, with EBIT projected to be 10% above consensus [3]. - Earnings per share (EPS) have dropped by 80% from their peak due to weakness in Asia, particularly in China and Hainan, but improved demand is anticipated in the upcoming quarters [5]. - The current trading multiple of 2.4x EV/sales indicates a significant discount compared to peers like L'Oréal, suggesting potential for a re-rating of the stock [7]. Group 2: Strategic Initiatives - The "Beauty Reimagined" strategy focuses on innovation speed, new channels, and cost efficiency, with a potential 10% reduction in headcount yielding up to $1 billion in savings, which may be reinvested into a 25% increase in brand and consumer marketing [4]. - The company generates $14 billion in revenue across 25 brands, positioning itself as the second-largest player in the $160 billion global prestige beauty market [4]. Group 3: Market Conditions - A more rational market environment during key shopping festivals and stabilizing trends in Hainan are expected to support growth in fiscal year 2026, while Korea's travel retail segment faces ongoing pressure [6].

Core Insights - The Estee Lauder Companies Inc. reported third-quarter fiscal 2025 results with both net sales and earnings declining year over year, primarily due to weak consumer sentiment and reduced conversion rates in China [1][2] Financial Performance - Adjusted earnings were 65 cents per share, surpassing the Zacks Consensus Estimate of 29 cents, but down 33% from 97 cents in the prior year [2] - Quarterly net sales reached $3,550 million, exceeding the Zacks Consensus Estimate of $3,507.2 million, but reflecting a 10% decline year over year [2] - Organic net sales decreased by 9% to $3,605 million [2] Category-Wise Revenue Results - Skin Care sales fell 12% year over year to $1,807 million, impacted by weak consumer sentiment and lower conversion rates among Chinese shoppers [3] - Makeup revenues declined 9% to $1,035 million, primarily due to weaker sales from key brands like M·A·C and Estée Lauder [4] - Fragrance revenues decreased 3% to $557 million, largely due to lower performance from Clinique and Estee Lauder [4] - Hair Care sales totaled $126 million, down 12% year over year, mainly due to Aveda's weaker performance [5] Regional Revenue Results - Sales in the Americas fell 6% year over year to $1,052 million [6] - Revenues in the EMEA region declined 18% to $1,358 million [6] - Asia-Pacific region sales tumbled 3% to $1,140 million [6] Margin Analysis - Adjusted gross margin improved by 310 basis points to 75%, driven by the Profit Recovery and Growth Plan (PRGP) [7] - Adjusted operating margin contracted by 270 basis points to 11.4%, due to increased investments and sales volume deleverage [8] Financial Health - The company exited the quarter with cash and cash equivalents of $2,631 million, long-term debt of $7,298 million, and total equity of $4,345 million [9] - Net cash flow from operating activities for the nine months ended March 31, 2025, was $671 million, with capital expenditures of $395 million [10] Restructuring and Future Outlook - The PRGP aims to transform the operating model, with expected restructuring charges between $1.2 billion and $1.6 billion before taxes [12][13] - The company anticipates a decline in reported net sales of 8-9% for fiscal 2025, with adjusted organic net sales expected to fall by the same percentage [14] - Adjusted EPS is projected to slump by 40-50%, ranging from $1.30 to $1.55 for fiscal 2025 [15]